Decreased Ferroportin Promotes Myeloma Cell Growth and Osteoclast Differentiation
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Iron homeostasis is disrupted in multiple myeloma, a difficult-to-cure plasma cell malignancy with lytic bone lesions. Here, we systematically analyzed iron gene expression signature and demonstrated that mRNA expression of iron exporter ferroportin (FPN1) is significantly downregulated in myeloma cells and correlates negatively with clinic outcome. Restoring expression of FPN1 reduces intracellular liable iron pool, inhibits STAT3-MCL-1 signaling, and suppresses myeloma cells growth. Furthermore, we demonstrated that mRNA of FPN1 is also downregulated at the initial stages of osteoclast differentiation and suppresses myeloma cell–induced osteoclast differentiation through regulating iron regulator TFRC, NF-κB, and JNK pathways. Altogether, we demonstrated that downregulation of FPN1 plays critical roles in promoting myeloma cell growth and bone resorption in multiple myeloma. Cancer Res; 75(11); 2211–21. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803 · cited 1×
“Hepcidin, the physiologic ligand of FPN1 (12), inhibits iron export by inducing internalization andproteasomedegradationof FPN1protein (13).”
BackgroundLipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron
Flo, T. H., Smith, K. D., Sato, S., Rodriguez, D. J., Holmes, M. A., Strong, R. K., Akira, S., & Aderem, A. (2004) · Nature · doi:10.1038/nature03104 · Cited by 1,877 · cited 1×
“Unlike multipleways of ironuptake bydifferent proteins such as TFRC(6) and lipocalin 2 (7), ferroportin (FPN1) is the only known exporter of iron in vertebrates (8).”
BackgroundCatlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Iron and cancer: more ore to be mined
Torti, S. V., & Torti, F. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3495 · Cited by 1,621 · cited 2×
“Many of these iron metabolic steps are altered in cancer, resulting in iron-related clinic symptoms such as anemia (1).”
BackgroundWnt signalling and its impact on development and cancer
Klaus, A., & Birchmeier, W. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2389 · Cited by 1,595 · cited 1×
“For instance, iron enhances colorectal tumorigenesis in the presence of APC mutations by augmenting WNT signaling and downregulating E-cadherin (5).”
BackgroundThe iron exporter ferroportin/Slc40a1 is essential for iron homeostasis
Donovan, A., Lima, C. A., Pinkus, J. L., Pinkus, G. S., Zon, L. I., Robine, S., & Andrews, N. C. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.01.003 · Cited by 1,275 · cited 1×
“Unlike multipleways of ironuptake bydifferent proteins such as TFRC(6) and lipocalin 2 (7), ferroportin (FPN1) is the only known exporter of iron in vertebrates (8).”
BackgroundBone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression
Babitt, J. L., Huang, F. W., Wrighting, D. M., Xia, Y., Sidis, Y., Samad, T. A., Campagna, J. A., Chung, R. T., Schneyer, A. L., Woolf, C. J., et al. (2006) · Nature Genetics · doi:10.1038/ng1777 · Cited by 1,026 · cited 2×
“Elevated IL6 and bone morphogenetic proteins (BMP) in the marrow of multiple myeloma patients are the primary cytokines that induce high expression of hepcidin (19, 20).”
BackgroundInterleukin-6 induces hepcidin expression through STAT3
Wrighting, D. M., & Andrews, N. C. (2006) · Blood · doi:10.1182/blood-2006-06-027631 · Cited by 983 · cited 2×
“Elevated IL6 and bone morphogenetic proteins (BMP) in the marrow of multiple myeloma patients are the primary cytokines that induce high expression of hepcidin (19, 20).”
BackgroundRegulation of Iron Metabolism by Hepcidin
Nemeth, E., & Ganz, T. (2006) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.26.061505.111303 · Cited by 756
Forging a field: the golden age of iron biology.
Andrews, N. C. (2008) · Blood · doi:10.1182/blood-2007-12-077388 · Cited by 623
Cited by
Regulators of Iron Homeostasis: New Players in Metabolism, Cell Death, and Disease
Bogdan, A. R., Miyazawa, M., Hashimoto, K., & Tsuji, Y. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.11.012 · Cited by 893
Insights Gained from Single-Cell Analysis of Immune Cells in the Tumor Microenvironment
Ren, X., Zhang, L., Zhang, Y., Li, Z., Siemers, N., & Zhang, Z. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-110519-071134 · Cited by 370
FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels
Trujillo-Alonso, V., Pratt, E. C., Zong, H., Lara-Martinez, A., Kaittanis, C., Rabie, M. O., Longo, V., Becker, M. W., Roboz, G. J., Grimm, J., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0406-1 · Cited by 319
Wang, Y., Yu, L., Ding, J., & Chen, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010095 · Cited by 294
Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents
Candelaria, P. V., Leoh, L. S., Penichet, M. L., & Daniels-Wells, T. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.607692 · Cited by 268
Metadata
- Authors
- Gu, Z., Wang, H., Xia, J., Yang, Y., Jin, Z., Xu, H., Shi, J., De Domenico, I., Tricot, G., & Zhan, F.
- Venue
- Cancer Research
- Published
- 2015-05-31
- Volume
- 75
- Issue
- 11
- Pages
- 2211-2221
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W1995264591
- Cited by
- 105
- References
- 18
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Decreased Ferroportin Promotes Myeloma Cell Growth and Osteoclast Differentiation. https://app.cochat.ai/papers/10.1158/0008-5472.can-14-3804
- The paper
- Gu, Z., Wang, H., Xia, J., Yang, Y., Jin, Z., Xu, H., Shi, J., De Domenico, I., Tricot, G., & Zhan, F. (2015). Decreased Ferroportin Promotes Myeloma Cell Growth and Osteoclast Differentiation. Cancer Research. https://doi.org/10.1158/0008-5472.can-14-3804
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.